This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutEfficacy & SafetyEfficacy &
SafetyOnce-Weekly ProphylaxisOn-Demand Bleed ControlSurgical EfficacyDosingSupport & ResourcesSupport & ResourcesEventsMaterialsVideosResources for Patients and CaregiversAdditional Resources
Related: See information on our hemophilia A productPrescribing Information Indication
BeneFIX Coagulation Factor IX (Recombinant): For once-weekly prophylaxis and on-demand use2ExperienceCommitted to the hemophilia B community for more than 20 years1,*
  • Over 20 studies, including more than 1500 patients3
  • More than 10 billion IU manufactured4
  • Available in hundreds of institutions nationwide4
  • 99% of commercially insured patients have access to BeneFIX4
Our clinical history1,2,4

rFIX, recombinant factor IX.

Complex protein production

Established cell line shown to be free of foreign agents and capable of producing large amounts of rFIX in an albumin-free medium5,6,†

Advanced purification

Customized purification processes designed with viral safety in mind5,6

Quality validation

Over 150 quality control examinations are performed on each batch of BeneFIX to help ensure a consistent purification process7

Chinese hamster ovary (CHO) cells used to manufacture BeneFIX are grown in media containing no added human or animal components.2References:Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. February 11, 1997. Accessed October 7, 2022. wayback.archive-it.org/7993/20170723024338/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htmBeneFIX. Prescribing information. Pfizer Inc.; 2021.US National Institutes of Health. ClinicalTrials.gov. Accessed October 7, 2022. https://www.clinicaltrials.govData on file. Pfizer Inc., New York, NY.Adamson S, Charlebois T, O'Connell B, Foster W. Viral safety of recombinant factor IX. Semin Hematol. 1998;35(2 suppl 2):22-27.Harrison S, Adamson S, Bonam D, et al. The manufacturing process for recombinant factor IX. Semin Hematol. 1998;35(2 suppl 2):4-10.Edwards J, Kirby N. Recombinant coagulation factor IX (BeneFIX). In: Walsh G, Murphy B, eds. Biopharmaceuticals, an Industrial Perspective. Kluwer Academic Publishers; 1999:73-108. Dosing options to meet patients' needs

Learn how you can personalize your patients’ dosing.

 See available vial sizes Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-BEN-USA-0773
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indication BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.  Limitation of use: BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B. Please see full Prescribing Information for BeneFIX.
Important Safety Information
  • BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein (CHO).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFIX. Closely monitor patients for signs and symptoms of acute anaphylaxis, particularly during the early phases of initial exposure to the product. Immediately discontinue the administration of the product and initiate appropriate treatment if symptoms occur.
  • Patients may develop hypersensitivity to hamster protein as BeneFIX contains trace amounts.
  • BeneFIX has been associated with the development of thromboembolic complications, including in patients receiving continuous infusion through a central venous catheter. The safety and efficacy of BeneFIX administration by continuous infusion have not been established.
  • Neutralizing antibodies (inhibitors) have been reported following the administration of BeneFIX. If expected plasma factor IX activity levels are not attained, or if the patient presents with an allergic reaction, or if bleeding is not controlled following an expected dose of BeneFIX, perform an assay that measures factor IX inhibitor concentration.
  • The most common adverse reactions (>5%) from clinical trials were fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness, and rash.
Indication BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.Limitation of use:BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.Please see full Prescribing Information for BeneFIX.